Prime Minister to Launch Nationwide HPV Vaccination Drive for 14-Year-Old Girls from Ajmer Tomorrow

1. At a Glance

• Nationwide HPV vaccination drive launched by PM Modi from Ajmer, Rajasthan on 28 February 2026, targeting ~1.15 crore girls aged 14 years annually [S1][S2].
• Anchored in the "Swastha Nari" vision; positioned as India's commitment to WHO's global strategy to eliminate cervical cancer as a public health problem [S1][S3].
• UPSC relevance: intersects GS-II (health, women, schemes) and GS-III (S&T, indigenous vaccines); aligns with Sustainable Development Goal 3.4 (NCD mortality reduction).

2. Why in the News

• 27 Feb 2026: PIB announced the nationwide rollout of the HPV vaccination programme to be launched the next day from Ajmer, Rajasthan [S1].
• States/UTs conducted simultaneous launch events; vaccine to be provided free-of-cost through the public health system [S2].

3. Background & Evolution

• 2008: HPV vaccines first introduced in India in the private market (Gardasil, Cervarix) [S5].
• Sep 2022: Union Minister Dr Jitendra Singh announced CERVAVAC, India's first indigenously developed quadrivalent HPV (qHPV) vaccine, by Serum Institute of India with DBT–BIRAC support under the Grand Challenges India programme with Bill & Melinda Gates Foundation [S5].
• Jun 2022: CDSCO Subject Expert Committee on Vaccines recommended marketing authorisation for ages 9–26 years [S5].
• Feb 2024 (Interim Budget): FM Nirmala Sitharaman announced government will encourage HPV vaccination for girls aged 9–14 to prevent cervical cancer [S6].
• Nov 2020: WHO launched Global Strategy to Accelerate the Elimination of Cervical Cancer (90-70-90 targets by 2030) [S3].
• 28 Feb 2026: Nationwide programme launched [S2].

4. Core Static Facts

• Implementing Ministry: Ministry of Health and Family Welfare (MoHFW) [S1].
• Vaccine used: Quadrivalent HPV vaccine (protects against HPV types 6, 11, 16, 18) — CERVAVAC by Serum Institute of India [S5].
• Target group (annual cohort): Girls aged 14 years; ~1.15 crore girls per year [S1].
• Launch site: Ajmer, Rajasthan; launched 28 Feb 2026 by PM Modi [S1][S2].
• WHO 90-70-90 target by 2030: 90% girls fully HPV-vaccinated by age 15; 70% women screened by ages 35 & 45; 90% of those with disease treated [S3].
• India cervical cancer burden (2022): 1,23,907 new cases; India accounts for >23% of global cervical cancer deaths [S4].
• Screening rate in India: only ~2% of eligible women [S4].

5. Multi-Dimensional Analysis

• Social / Gender: Cervical cancer is the 2nd most common cancer among Indian women; vaccination redresses the disproportionate burden on lower-socioeconomic strata where screening access is poor [S4]. "Swastha Nari" framing situates it within women-centric health policy [S1].
• Scientific / Technological: Demonstrates Atmanirbhar Bharat in biotech — indigenously developed CERVAVAC reduces cost vs imported Gardasil/Cervarix; product of public-private R&D (DBT-BIRAC + SII + Gates Foundation) [S5].
• Economic / Fiscal: Free public delivery lowers out-of-pocket health expenditure; per IARC modelling, full 90-70-90 implementation in India requires USD 1.986 billion over 10 years and ~15.6 crore HPV doses [S4].
• Public Health Governance: First major NIP-style addition since rotavirus/PCV; tests cold-chain, U-WIN registry, and school-based delivery capacity. Federal cooperation needed as Health is a State subject (List II).
• Geopolitical: Reinforces India's role under Quad Cancer Moonshot Initiative (2024) for the Indo-Pacific cervical cancer fight [S7].

6. Recent Developments (last 12-18 months)

• 1 Feb 2024: Interim Union Budget announcement on HPV vaccination for 9-14 year-old girls [S6].
• 21 Sep 2024: Quad Leaders' Summit launched the Cancer Moonshot Initiative focused on cervical cancer in Indo-Pacific [S7].
• 27 Feb 2026: PIB release announcing nationwide rollout [S1].
• 28 Feb 2026: PM Modi launches programme from Ajmer; states hold parallel events [S2].

7. Prelims Hooks

• HPV vaccination drive launched from Ajmer, Rajasthan on 28 Feb 2026 [S1][S2].
• Annual target cohort: ~1.15 crore girls aged 14 [S1].
• CERVAVAC — India's first indigenously developed qHPV vaccine, by Serum Institute of India, announced Sep 2022 [S5].
• CERVAVAC developed under DBT–BIRAC's Grand Challenges India with Bill & Melinda Gates Foundation [S5].
• HPV vaccine targets HPV types 6, 11, 16, 18 (16 and 18 cause ~70% of cervical cancers) [S5].
• WHO 90-70-90 strategy launched in November 2020, target year 2030 [S3].
• India recorded 1,23,907 new cervical cancer cases in 2022 [S4].
• India accounts for >23% of global cervical cancer deaths [S4].
• Cervical cancer screening coverage in India: ~2% [S4].
• Vision tagline: "Swastha Nari" [S1].
• Implementing ministry: Ministry of Health and Family Welfare (not Ministry of Women & Child Development) [S1].
• HPV vaccination first promoted in Interim Budget 2024-25 by FM Sitharaman [S6].
• Quad Cancer Moonshot Initiative (2024) focuses on cervical cancer in Indo-Pacific [S7].

8. Mains Relevance

• GS-II: "Issues relating to development & management of Social Sector/Services relating to Health"; "Welfare schemes for vulnerable sections… women".
• GS-III: "Indigenisation of technology and developing new technology"; biotechnology.
• Probable question stems: 1. "India's nationwide HPV vaccination drive is as much a feat of indigenous biotechnology as it is of public health governance." Discuss. 2. Examine the challenges in achieving WHO's 90-70-90 cervical cancer elimination targets in India by 2030. 3. Discuss the role of public-private partnerships (DBT-BIRAC, SII, Gates Foundation) in India's vaccine self-reliance, with reference to CERVAVAC.

9. Related Topics to Study Next

• Universal Immunisation Programme (UIP) & Mission Indradhanush — base immunisation platform onto which HPV is being added.
• U-WIN portal — digital backbone for non-COVID vaccination tracking.
• National Cancer Control Programme / NP-NCD — cervical cancer screening pillar.
• CDSCO and Subject Expert Committee — regulatory pathway used for CERVAVAC.
• DBT-BIRAC & Grand Challenges India — biotech PPP model.
• Quad Cancer Moonshot (2024) — geopolitical dimension.
• WHO Global Strategy on Cervical Cancer Elimination (2020) — international anchor.
• Ayushman Bharat – PMJAY & Health & Wellness Centres — screening/treatment linkage.

10. Common Errors / Trap Areas

• HPV vaccine is quadrivalent (4 types: 6, 11, 16, 18) for CERVAVAC — not bivalent (Cervarix) or nonavalent (Gardasil-9) [S5].
• Implementing ministry is MoHFW, not MoWCD — despite "Nari" framing [S1].
• WHO target year is 2030, but India's modelled elimination (incidence <4/100,000) only by 2062 under 90-70-90 [S4].
• CERVAVAC's licensure age band is 9-26, but the nationwide programme targets 14-year-old girls as the annual school-age cohort [S1][S5].
• HPV vaccination first announced in Interim Budget 2024, launched in Feb 2026 — don't conflate.

11. Sources

• [S1] Prime Minister to Launch Nationwide HPV Vaccination Drive for 14-Year-Old Girls from Ajmer Tomorrow — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233632 — (tier: 1)
• [S2] Cervical Cancer Vaccination Campaign Launched — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2234009 — (tier: 1)
• [S3] WHO Cervical Cancer Elimination Initiative (90-70-90 strategy, 2020) — https://www.who.int/initiatives/cervical-cancer-elimination-initiative — (tier: 2)
• [S4] IARC/WHO Elimination Planning Tool — India Factsheet — https://gco.iarc.who.int/media/elimination_tool/factsheets/356-IND-india.pdf — (tier: 2)
• [S5] Union Minister announces India's first indigenously developed vaccine "CERVAVAC" — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1856034 — (tier: 1)
• [S6] 'Nari Shakti' takes centre stage; FM announces vaccination to prevent cervical cancer (Interim Budget 2024) — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2001172 — (tier: 1)
• [S7] Quad Countries Launch Cancer Moonshot Initiative — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2057459 — (tier: 1)